In cases where EGFR NSCLC has transformed into small-cell lung cancer after treatment with osimertinib, and with no CNS involvement, is it advisable to continue osimertinib alongside chemotherapy?

There is a paucity of data to guide treatment decisions in this context. Transformed small cell lung cancer is a complex phenomenon wherein some oncogene-driven lung cancer clones undergo a series of transcriptomic and epigenetic changes (such as EMT-like changes and methylation-driven events) as a ...

Also, tarlatamab doesn’t work well in these despite high DLL3 expression, per this small series Cooper et al., PMID 41166675.